Senl 1904B / SenlangBio - LARVOL DELTA

Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction (GlobeNewswire) - "Senl_NS7CAR:...Clinical stage and data: Successfully completed PI-initiated first-in-human clinical trial; 8 out of 8 T-ALL and T-LBL patients achieved complete remission, and none developed greater than Grade 2 CRS; plan to file an IND application with the NMPA around the third quarter of 2021 and start an official Phase I clinical trial upon approval of the IND application...CAR-γδT cell-therapy candidates:...Clinical stage and data: Successfully completed pre-clinical, IND-enabling stage and currently in preparation to initiate 3-4 PI-initiated first-in-human clinical trials targeting AML, MDS and solid tumors around the fourth quarter of 2021."

New P1 trial • Non-US regulatory • Preclinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Acute Lymphoblastic Leukemia

Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction (GlobeNewswire) - "Avalon GloboCare Corp...announced that it has entered into a definitive agreement to acquire Hebei Senlang Biotechnology Co. Ltd. ('SenlangBio'), a PRC limited liability company...Senl_1904B:...Recently received approval of Investigational New Drug (IND) application by China’s National Medical Products Administration (NMPA) to initiate Phase I clinical trial in R/R B-ALL during the third quarter of 2021."

M&A • New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Hebei Senlang Biotechnology Inc., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2020 ➔ Jan 2022; Trial primary completion date: Sep 2019 ➔ Sep 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19